US 9345780
Site specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
granted A61KA61K47/545A61K47/549
Quick answer
US patent 9345780 (Site specific delivery of nucleic acids by combining targeting ligands with endosomolytic components) held by Tekmira Pharmaceuticals Corporation expires Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Tekmira Pharmaceuticals Corporation
- Grant date
- Tue May 24 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 10
- CPC classes
- A61K, A61K47/545, A61K47/549, A61K47/551, A61K47/554